- Home
- NFGC vs DAWN Comparison
NFGC vs DAWN Comparison
Compare NFGC & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NFGC | DAWN |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 908.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NFGC | DAWN |
|---|---|---|
| Price | $3.01 | $8.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $5.00 | ★ $26.75 |
| AVG Volume (30 Days) | 1.9M | ★ 2.2M |
| Earning Date | 11-07-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $133,672,000.00 |
| Revenue This Year | N/A | $15.51 |
| Revenue Next Year | $1,903.79 | $49.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.11 |
| 52 Week Low | $0.93 | $5.64 |
| 52 Week High | $3.32 | $13.53 |
Technical Indicators
Market Signals| Indicator | NFGC | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 51.27 |
| Support Level | $2.92 | $8.35 |
| Resistance Level | $3.23 | $9.71 |
| Average True Range (ATR) | 0.18 | 0.49 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 56.25 | 45.96 |
Price Performance
Historical ComparisonAbout NFGC New Found Gold Corp
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Company's exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.